Reforgene Medicine at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Reforgene Medicine brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on editing a patient's own blood stem cells to restore haemoglobin. Topics include lasting clinical benefit in transfusion-dependent beta-thalassemia and the same approach applied to haemoglobin H-Constant Spring.
| Organization | ESGCT 2026 Attendance |
|---|---|
Reforgene Medicine Guangzhou, China | |
Chinese gene editing company developing edited blood stem cell therapies, including RM001 for transfusion-dependent beta-thalassemia. | Talk Tue Oct 27 6:45pm–7:30pm Durable clinical benefits with RM001 (Autologous HBG1/2 Promoter-modified CD34+ Hematopoietic Stem and Progenitor Cells) for transfusion-dependent beta-thalassemia Gene and epigenome editingRare and inherited disease Poster Thu Oct 29 2:00pm–4:00pm Curing transfusion-dependent hemoglobin H-Constant Spring via ex vivo gene editing of autologous hematopoietic stem cells |
Instantly find 20 buyers from Reforgene Medicine
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction